Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis

Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis

IntroductionLimited survival data are available for patients with metastatic non-small cell lung cancer (mNSCLC) who stop immune checkpoint inhibitor therapy (ICI) early for reasons other than progression of disease (POD), such as immune-related adverse events (irAEs).MethodsWe conducted a retrospec...

Full description

Bibliographic Details
Main Authors: Blake J. McKinley, Tanmayi S. Pai, Emily B. Wolf, Shenduo Li, Guilherme Sacchi de Camargo Correia, Yujie Zhao, Rami Manochakian, Yanyan Lou
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-06-01
Series:Frontiers in Oncology
Subjects:
NSCLC
early discontinuation
progression-free survival
overall survival
stage IV
metastatic
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1417175/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1417175/full

Similar Items